Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Actin Filament Depolymerization01:19

Actin Filament Depolymerization

4.3K
Actin filaments (F-actin) are composed of actin subunits. The dissociation of actin monomers can occur from either end of F-actin. The rate of dissociation is faster from the minus-end or the pointed end, where the actin subunits exist with a bound ADP, together known as ADP-actin. The depolymerization of F-actin is aided by proteins, including the actin-depolymerizing factor (ADF) and cofilin family of proteins, gelsolin, and glia maturation factor (GMF).
In F-actin, the ADF/cofilin proteins...
4.3K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Water-stable α-cyclodextrin encapsulated CsPbBr<sub>3</sub> perovskite quantum dots for fluorescence detection of propiconazole.

Mikrochimica acta·2026
Same author

A Combined Approach: Karyotyping and QF-PCR for Comprehensive Genetic Screening in Male Infertility.

Biochemical genetics·2026
Same author

PPa1 insufficiency drives lysosomal storage disease and inflammatory macrophage expansion in the bone marrow.

bioRxiv : the preprint server for biology·2026
Same author

Ovarian Rev-erbα: a central regulator of fertility following chronodisruption.

Frontiers in endocrinology·2026
Same author

Bismuth Bicycles.

Journal of peptide science : an official publication of the European Peptide Society·2026
Same author

Harnessing Genetic Engineering for Petrochemical Waste Detoxification: Mechanisms and Recent Breakthroughs.

Journal of basic microbiology·2026

Related Experiment Video

Updated: Apr 19, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

12.1K

Plasma gelsolin levels decrease in diabetic state and increase upon treatment with F-actin depolymerizing versions of

Neeraj Khatri1, Amin Sagar1, Nagesh Peddada1

  • 1CSIR-Institute of Microbial Technology, Sector 39-A, Chandigarh 160036, India.

Journal of Diabetes Research
|December 6, 2014
PubMed
Summary
This summary is machine-generated.

Plasma gelsolin (pGSN) levels are lower in type II diabetes. Gelsolin therapy effectively lowers blood sugar in diabetic mice, suggesting its potential role in diabetes management.

More Related Videos

Observing and Quantifying Fibroblast-mediated Fibrin Gel Compaction
10:37

Observing and Quantifying Fibroblast-mediated Fibrin Gel Compaction

Published on: January 16, 2014

6.5K
Polyacrylamide Gels for Invadopodia and Traction Force Assays on Cancer Cells
08:48

Polyacrylamide Gels for Invadopodia and Traction Force Assays on Cancer Cells

Published on: January 4, 2015

12.8K

Related Experiment Videos

Last Updated: Apr 19, 2026

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States
07:09

Experimental and Imaging Techniques for Examining Fibrin Clot Structures in Normal and Diseased States

Published on: April 1, 2015

12.1K
Observing and Quantifying Fibroblast-mediated Fibrin Gel Compaction
10:37

Observing and Quantifying Fibroblast-mediated Fibrin Gel Compaction

Published on: January 16, 2014

6.5K
Polyacrylamide Gels for Invadopodia and Traction Force Assays on Cancer Cells
08:48

Polyacrylamide Gels for Invadopodia and Traction Force Assays on Cancer Cells

Published on: January 4, 2015

12.8K

Area of Science:

  • Biochemistry
  • Endocrinology
  • Molecular Biology

Background:

  • Type II diabetes is a global health concern characterized by hyperglycemia.
  • Plasma gelsolin (pGSN) is an actin-binding protein with potential roles in inflammation and cell survival.
  • Reduced pGSN levels have been observed in various disease states, but their specific role in type II diabetes requires further investigation.

Purpose of the Study:

  • To quantify plasma gelsolin levels in human and murine models of type II diabetes.
  • To assess the therapeutic efficacy of gelsolin and its variants in improving glycemic control in diabetic mice.
  • To explore the relationship between gelsolin levels and blood glucose regulation during diabetes treatment.

Main Methods:

  • Measurement of plasma gelsolin levels in type II diabetic patients and a mouse model.
  • Subcutaneous administration of recombinant plasma gelsolin and its functional variants to diabetic mice.
  • Oral glucose tolerance tests (OGTT) to evaluate glucose metabolism.
  • Comparison of gelsolin therapy with Sitagliptin, a standard anti-diabetic drug.
  • Monitoring of plasma gelsolin and blood glucose levels before and after treatment.

Main Results:

  • Plasma gelsolin levels were significantly reduced (0.45-0.5 fold) in both human and mouse models of type II diabetes.
  • Recombinant pGSN administration, including its F-actin depolymerizing variants, effectively lowered blood glucose levels in diabetic mice, comparable to Sitagliptin.
  • Daily administration of pGSN or its truncated versions for one week maintained blood sugar levels near normal in diabetic mice.
  • Treatment with Sitagliptin led to increased pGSN levels alongside decreased blood glucose in diabetic mice.

Conclusions:

  • Plasma gelsolin levels are diminished in type II diabetes.
  • Gelsolin therapy demonstrates significant potential for improving glycemic control in type II diabetes.
  • Monitoring gelsolin levels and considering gelsolin replacement therapy, particularly F-actin severing capable forms, may be beneficial in managing diabetes.